EFICÁCIA COMPARATIVA DE PSICODÉLICOS (PSILOCIBINA E MDMA) NO TRATAMENTO DE TRANSTORNO DE ESTRESSE PÓS-TRAUMÁTICO E DEPRESSÃO RESISTENTE AO TRATAMENTO: REVISÃO SISTEMÁTICA
Asclepius International Journal of Scientific Health Science July 5, 2026 Pedro Martins Rabelo
A systematic review of eight randomized controlled trials found that psilocybin (25 mg) produced clinically significant reductions in depressive symptoms on the MADRS and QIDS-SR‑16 scales in treatment-resistant depression, while MDMA‑assisted therapy reduced CAPS‑5 scores in post‑traumatic stress disorder, with 67–71% of participants no longer meeting diagnostic criteria after treatment. Both substances had acceptable safety profiles with mostly transient adverse events. Direct comparative meta‑analysis was not possible due to clinical and methodological heterogeneity. Limitations include small samples, blinding difficulties, and lack of long‑term follow‑up.